Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

EMCURE PHARMACEUTICALS LTD.

NSE : EMCUREBSE : 544210ISIN CODE : INE168P01015Industry : Pharmaceuticals & DrugsHouse : Private

BSE1439.6030.7 (+2.18 %)

PREV CLOSE ( ) 1408.90

OPEN PRICE ( ) 1419.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 5987

TODAY'S LOW / HIGH ( )1406.60 1465.50

52 WK LOW / HIGH ( )890 1524.85

NSE1438.6029.3 (+2.08 %)

PREV CLOSE( ) 1409.30

OPEN PRICE ( ) 1409.40

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1438.60 (3)

VOLUME 177399

TODAY'S LOW / HIGH( ) 1408.00 1469.00

52 WK LOW / HIGH ( )889 1519.9

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 16-04 1981

Management Info

Berjis Desai - Chairman Satish Mehta - Managing Director

Registered Office

Address Plot No. P-1 & P-2,I T - B T Park, Phase- I I,M I D C, Hinjawadi,
Pune,
Maharashtra-411057

Phone 020-35070033 / 35070000

Email corporate@emcure.com

Website www.emcure.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

27Nov Emcure Pharmaceuticals informs about d
Emcure Pharmaceuticals has informed that it enclosed the disclosure rega..

22Nov Emcure Pharmaceuticals informs about r
Emcure Pharmaceuticals has informed that Mr. Chetan Sharma (FCS:8352) ha..

19Nov Emcure Pharmaceuticals informs about
In continuation to letter dated November 14, 2025 and pursuant to the pr..

10Nov Emcure Pharma, Novo Nordisk India join
Emcure Pharmaceuticals and Novo Nordisk India have entered into a strate..

06Oct Emcure Pharmaceuticals surges on acqui
Emcure Pharmaceuticals is currently trading at Rs. 1398.35, up by 58.05..

Financials

Rs. in Millions

	QTR Sep 25	ANNUAL 25
Net Profit	1176.22	3171.28
Gross Profit	1578.91	4277.1
Operating Profit	2473.44	7656.44
Net Sales	12606.04	43819.24

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE) 1128.80 (6.39%)	M.Cap ( in Cr)777.96
Amrutanjan Healthcar (BSE) 689.65 (6.38%)	M.Cap ( in Cr)1993.82
Lupin (BSE) 2114.10 (1.62%)	M.Cap ( in Cr)96571.84
Panacea Biotec (BSE) 362.70 (9.53%)	M.Cap ( in Cr)2221.56
Aurobindo Pharma (BSE) 1193.70 (1.81%)	M.Cap ( in Cr)69330.29

Shareholding Pattern

	PROMOTERS	77.88%
	NON-INSTITUTION	14.46%
	MUTUAL FUNDS/UTI	3.58%
	FI/BANKS/INSURANCE	0.49%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Bajaj Finserv Healt...	3.19
Aditya Birla SL Pha...	2.74
WOC Pharma and Heal...	1.99
DSP Healthcare Fund...	1.45
Edelweiss Recently ...	1.32
Aditya Birla SL Bal...	1.12
Aditya Birla SL Ret...	1.02

Risk Disclosures on Derivatives

Smart Quotes

EMCURE PHARMACEUTICALS LTD.